Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences (GILD) Q2 Earnings Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.

Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More

Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

Style Box ETF report for ONEY

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

Smart Beta ETF report for ONEY

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.

Yashwardhan Jain headshot

Is Now the Right Time to Embrace Biotech ETFs?

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?

Smart Beta ETF report for CLRG

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.

Shaun Pruitt headshot

2 Medical Stocks to Consider Buying in June

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.

Gilead Sciences (GILD) Announces Positive HDV Treatment Data

Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.

Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.

Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data

Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.